Monte Rosa Therapeutics
GLUE
48 hedge funds and large institutions have $705M invested in Monte Rosa Therapeutics in 2021 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
72.14% more ownership
Funds ownership: 0% → 72.14% (+72%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$157M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.8M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$67.4M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$65.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$55.8M |
Top Sellers
GLUE Hedge Fund Activity: Q2 2021 in Review
48 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2021, worth a combined $705M.
Buyers outnumbered sellers: 48 funds opened new GLUE positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $157M.
- 48 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $705M of Monte Rosa Therapeutics stock for Q2 2021.
- 48 funds opened new Monte Rosa Therapeutics positions in Q2 2021 and 0 closed out, a net change of +48 holders.
- The largest Monte Rosa Therapeutics buyer in Q2 2021 was NEA Management Company, an estimated $157M added.
Based on aggregated 13F filings for Q2 2021.